The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, FIZZ, RMTI, TTPH and FB
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 to July 9, 2018 Lead Plaintiff Deadline: September 17, 2018
The complaint alleges that during the class period ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the ACAD lawsuit: http://www.kleinstocklaw.com/pslra-c/acadia-pharmaceuticals-inc?wire=3
National Beverage Corp. (NASDAQ: FIZZ)Class Period: July 17, 2014 to July 3, 2018Lead Plaintiff Deadline: September 17, 2018
The lawsuit alleges that National Beverage Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) National Beverage’s sales claims and its supposed “proprietary techniques” lacked a verifiable basis; (2) the Company’s Chairman and CEO engaged in a pattern of sexual misconduct between 2014 and 2016; and (3) as a result, National Beverage’s public statements were materially false and misleading at all relevant times.
On May 4, 2017, National Beverage issued a press release stating that it “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).” National Beverage asserted that it “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” Then on June 26, 2018 the Wall Street Journal reported that National Beverage had declined to provide the U.S. Securities and Exchange Commission with requested sales figures to clarify their sales claims. Then on July 3, 2018, the Wall Street Journal published an article reporting that two pilots had filed lawsuits alleging that National Beverage’s CEO had sexually harassed them.
Get additional information about the FIZZ lawsuit: http://www.kleinstocklaw.com/pslra-c/national-beverage-corp?wire=3
Rockwell Medical, Inc. (NASDAQ: RMTI) Class Period: November 8, 2017 to June 26, 2018 Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that during the class period Rockwell Medical, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
Get additional information about the RMTI lawsuit: http://www.kleinstocklaw.com/pslra-c/rockwell-medical-inc?wire=3
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) Class Period: (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018 Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (3) consequently, Defendants’ statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Get additional information about the TTPH lawsuit: http://www.kleinstocklaw.com/pslra-c/tetraphase-pharmaceuticals-inc?wire=3
Facebook, Inc. (NASDAQ: FB) Class Period: October 1, 2017 to July 26, 2018 Lead Plaintiff Deadline: September 25, 2018
The complaint alleges Facebook, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the implementation of the General Data Protection Regulation (“GDPR”), which was adopted by the European Union on or around April 14, 2016, would have a foreseeable and materially negative impact on use of the Platform, revenue growth, and profitability because the informed consent required by the GDPR resulted in many users rejecting Facebook’s privacy policies and/or procedures and exposed a significant number of fake accounts on the platform; (ii) by May 25, 2018, Facebook’s Platform use and revenue growth had already begun to decline as a result of Facebook’s efforts to comply with the GDPR; (iii) the decline in Facebook’s Platform use and the increase in costs as a result of complying with the GDPR had a materially adverse effect on Facebook’s financial health, including its revenue and projected growth; and (iv) as a result, Facebook’s public statements were materially false and misleading at all relevant times.
Get additional information about the FB lawsuit: http://www.kleinstocklaw.com/pslra-c/facebook-inc-3?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.